Literature DB >> 16203034

Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma.

L Jeffrey Medeiros1, Zeev Estrov, George Z Rassidakis.   

Abstract

The Z-138 cell line, reported in the journal in 1998, was derived from a patient who developed a leukemia initially classified as chronic lymphocytic leukemia in 1987. Splenectomy for massive involvement was required in 1998 and the neoplasm subsequently transformed to an aggressive, mature B-cell leukemia 2 years later. At time of transformation, the neoplasm had a complex karyotype, including the t(11;14)(q13;q32). In light of the extensive updates in lymphoma classification that have occurred since that time, we reviewed the slides of the patient's neoplasm. The initial peripheral blood and bone marrow aspirate smears and the spleen were involved by numerous small lymphocytes with mature chromatin. The last bone marrow specimen was involved by slightly larger, irregular lymphocytes with immature chromatin and a high mitotic rate. Immunohistochemical analysis performed on the spleen and last bone marrow for this report showed that the neoplastic cells over-expressed cyclin D1. According to the criteria of the current World Health Organization lymphoma classification, this neoplasm is best classified as mantle cell lymphoma, with blastoid transformation present in the terminal phase of disease.

Entities:  

Mesh:

Year:  2005        PMID: 16203034     DOI: 10.1016/j.leukres.2005.08.026

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.

Authors:  Martina Rudelius; Stefania Pittaluga; Satoshi Nishizuka; Trinh H-T Pham; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martinez; Mark Raffeld
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

2.  Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.

Authors:  Paolo Conrotto; Ulrika Andréasson; Venera Kuci; Carl A K Borrebaeck; Sara Ek
Journal:  Mol Oncol       Date:  2011-08-22       Impact factor: 6.603

3.  Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.

Authors:  Lan V Pham; Muychi T Vang; Archito T Tamayo; Gary Lu; Pramoda Challagundla; Jeffrey L Jorgensen; Alex A Rollo; Zhishuo Ou; Liang Zhang; Michael Wang; Richard J Ford
Journal:  Leuk Lymphoma       Date:  2014-04-29

4.  Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

Authors:  Evangelia Peponi; Elias Drakos; Guadalupe Reyes; Vasiliki Leventaki; George Z Rassidakis; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

5.  Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Authors:  Lan V Pham; Archito T Tamayo; Changping Li; William Bornmann; Waldemar Priebe; Richard J Ford
Journal:  Mol Cancer Ther       Date:  2010-07-06       Impact factor: 6.261

6.  Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Authors:  Adrian Wiestner; Mahsa Tehrani; Michael Chiorazzi; George Wright; Federica Gibellini; Kazutaka Nakayama; Hui Liu; Andreas Rosenwald; H Konrad Muller-Hermelink; German Ott; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; Julie Vose; James O Armitage; Randy D Gascoyne; Joseph M Connors; Elias Campo; Emilio Montserrat; Francesc Bosch; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard I Fisher; Thomas M Grogan; Thomas P Miller; Wyndham H Wilson; Elaine S Jaffe; Louis M Staudt
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

7.  Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

Authors:  Sabrina Donnou; Claire Galand; Valérie Touitou; Catherine Sautès-Fridman; Zsuzsanna Fabry; Sylvain Fisson
Journal:  Adv Hematol       Date:  2012-02-12

8.  Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.

Authors:  Kazumasa Sekihara; Kaori Saitoh; Lina Han; Stefan Ciurea; Shinichi Yamamoto; Mika Kikkawa; Saiko Kazuno; Hikari Taka; Naoko Kaga; Hajime Arai; Takashi Miida; Michael Andreeff; Marina Konopleva; Yoko Tabe
Journal:  Oncotarget       Date:  2017-05-23

9.  Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.

Authors:  Catja Freiburghaus; Venera Kuci Emruli; Angelica Johansson; Christian Winther Eskelund; Kirsten Grønbæk; Roger Olsson; Fredrik Ek; Mats Jerkeman; Sara Ek
Journal:  BMC Cancer       Date:  2018-04-25       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.